Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2024-05-08 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
昆药集团关于参加云南辖区上市公司2023年度投资者网上集体接待日活动的公告
Regulatory Filings Classification · 80% confidence The document is an announcement about the company's participation in an investor online collective reception day event, where company executives will discuss the 2023 annual and 2024 Q1 performance, governance, strategy, and sustainability. It is a notice of an upcoming investor interaction event rather than a report or transcript of the event. The document length is short (606 characters) and does not contain financial statements or detailed financial data. It is not a transcript, report, or regulatory filing but an announcement related to investor relations activities. Therefore, the best fitting category is Investor Presentation (IP), as it relates to a presentation or communication aimed at investors, even though it is an announcement of the event rather than the presentation itself. However, since it is primarily an announcement of participation in an investor event, and not the presentation content itself, the classification leans towards Regulatory Filings (RNS) as a fallback for miscellaneous announcements that do not fit other categories better. Given the content and length, RNS is the most appropriate classification with moderate confidence.
2024-05-08 Chinese
昆药集团股份有限公司股东大会议事规则 (2024年4月修订）
Governance Information Classification · 95% confidence The document is titled as the "Rules of Procedure for the Shareholders' General Meeting" of Kunming Pharmaceutical Group Co., Ltd., dated April 19, 2024. It details the procedures, rights, and regulations governing the conduct of shareholders' meetings, including notice requirements, proposal submissions, voting procedures, meeting records, and disclosure obligations. It does not contain financial statements, audit opinions, earnings data, or any direct financial results. Instead, it is a governance document outlining internal rules and processes related to shareholder meetings. Therefore, it fits best under the category of Governance Information (CGR). The document length (8171 characters) and content confirm it is a full governance report, not a brief announcement or a notice.
2024-04-19 Chinese
昆药集团2024年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2024 年第一季度报告' which translates to '2024 First Quarter Report'. It contains detailed financial data including consolidated balance sheets, profit and loss statements, and cash flow statements for the first quarter of 2024. The report includes unaudited financial statements, management commentary on business strategy, shareholder information, and other operational details. The presence of comprehensive quarterly financial statements and analysis indicates this is an Interim / Quarterly Report. The document length is over 14,000 characters, and it contains substantive financial data, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2024-04-19 Chinese
昆药集团2024年第三次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2024 third extraordinary general meeting of shareholders of Kunming Pharmaceutical Group Co., Ltd. It includes information about the meeting date, attendance, voting results on various proposals, and legal witness statements. The content focuses on the voting outcomes and procedural compliance of the shareholders' meeting. It is not a full annual or interim report, nor a financial statement or earnings release. It is not a proxy solicitation or a remuneration report. The document is clearly an official announcement of voting results from a shareholders' meeting, which fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 2567 characters, which is sufficient to contain detailed voting results rather than just a brief notice or report publication announcement. Therefore, the classification is DVA with high confidence.
2024-04-19 Chinese
昆药集团十届二十三次监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a supervisory board resolution announcement from Kunming Pharmaceutical Group regarding the approval of the company's 2024 first quarter report. It states that the first quarter report was published on the Shanghai Stock Exchange website and includes the supervisory board's written review opinion confirming compliance with laws and regulations. The document itself does not contain the full quarterly report or detailed financial data but rather announces the supervisory board's approval and review of the report. The document length is short (621 characters), and it serves as an announcement related to the quarterly report rather than the report itself. Therefore, it fits best under Regulatory Filings (RNS) as a formal announcement of supervisory board approval and review, not the full Interim/Quarterly Report (IR).
2024-04-19 Chinese
昆药集团股份有限公司章程 (2024年4月修订）
Governance Information Classification · 100% confidence The document is titled as the Articles of Association (章程) of Kunming Pharmaceutical Group Co., Ltd. It contains detailed chapters on company governance, shareholder rights, board structure, share issuance, share repurchase, and other corporate governance matters. It references legal frameworks such as the Company Law and Securities Law, and includes detailed provisions on shares, shareholders, board of directors, supervisory board, financial accounting, profit distribution, audits, and amendments to the articles. The document is lengthy (15,000 characters) and is a comprehensive governance document rather than a report of financial results or an announcement. It is not an annual report, earnings release, or any other financial report. It is a governance document detailing the company's internal rules and governance practices. Therefore, the appropriate classification is Governance Information (CGR).
2024-04-19 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.